SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitwise XRP ETF - Common Shares Of Beneficial Interest

Bitwise XRP ETF

XRP is trending due to intensifying institutional adoption, marked by its integration into major banking infrastructures and the steady performance of its spot ETFs, which have recorded a significant streak of consecutive inflows. The community is actively discussing the asset's long-term utility in global financial settlement, potential regulatory clarity, and its expanding role in tokenizing real-world assets, while keeping a watchful eye on price volatility.

Amkor Technology, Inc. engages in the provision of outsourced semiconductor packaging and test services. Its services include design, package characterization, test, and wafer bumping services. The company was founded in 1968 and is headquartered in Tempe, AZ.

AMKOR Technology Inc.

Amkor Technology is trending as market participants focus on the company's critical role in the AI supply chain, particularly following major expansions in its U.S. advanced packaging capacity. The community is actively discussing the stock's role as an 'AI infrastructure' play, with traders closely tracking potential breakouts as it gains momentum alongside broader semiconductor and industrial leaders hitting new highs.

Albemarle Corp. engages in the development, manufacture, and marketing of chemicals for consumer electronics, petroleum refining, utilities, packaging, construction, transportation, pharmaceuticals, crop production, food-safety, and custom chemistry services. It operates through the following segments: Energy Storage, Specialties, and Ketjen. The Energy Storage segment develops and manufactures a broad range of basic lithium compounds, including lithium carbonate, lithium hydroxide, and lithium chloride. The Specialties segment focuses on optimizing a portfolio of bromine and specialized lithium solutions. The Ketjen segment consists of clean fuels technologies, fluidized catalytic cracking catalysts and additives, and performance catalyst solutions, which is primarily composed of organometallics and curatives. The company was founded in 1993 and is headquartered in Charlotte, NC.

Albemarle Corp.

Albemarle Corp

Albemarle is experiencing a strong rally as community sentiment shifts, driven by a rebound in lithium spot prices and increasing demand from utility-scale energy storage projects. Investors are actively discussing the stock's breakout potential as the sector shows signs of recovering from cyclical lows, while attention remains fixed on supply-side constraints and the role of critical minerals in the ongoing electrification of the grid.

The TROLL token on the Solana network is a meme coin inspired by internet trolling culture, designed for entertainment and community engagement with no intrinsic value. Built on Solana’s blockchain, it leverages the network’s fast transactions and low fees to appeal to meme enthusiasts. Launched on decentralized exchanges, TROLL aims to foster a fun, community-driven ecosystem through social media, influencer partnerships, and viral marketing, embodying the playful spirit of online trolling.

Troll

Troll is gaining momentum as market participants increasingly highlight its status as an established meme with original IP rights and a growing community presence. Investors are actively drawing parallels to past major market cycles while debating its potential for future growth alongside other prominent meme-sector assets.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is gaining traction as traders rotate back into AI and IoT-linked tokens, with the community closely tracking potential ecosystem expansion and technical breakout patterns. Sentiment remains divided between long-term holders betting on utility-driven adoption in Japan and skeptical traders who view recent price action as speculative volatility.

Litecoin is a decentralized, peer-to-peer digital currency designed to enable instant, near-zero cost payments to individuals and merchants worldwide. As an open-source global payment network that functions independently of central banks or intermediaries, its main value proposition lies in providing a scarce digital asset with a fixed maximum supply of 84 million tokens.  The network operates using a Proof of Work mechanism where computers solve complex puzzles to confirm transactions and secure the blockchain. It is distinguished by a block generation time of 2.5 minutes, which allows for faster transaction confirmations and a higher total throughput than earlier protocols. Key technical features include the Scrypt hashing algorithm, which promotes wider network participation, and MimbleWimble Extension Blocks, which improve user privacy by allowing transaction details to be hidden.  The LTC token is used for settling global payments, executing microtransactions through smaller units called litoshis, and diversifying digital portfolios with a highly liquid asset. New tokens are issued to miners as rewards for verifying blocks, though these rewards undergo a halving event approximately every four years to strictly control inflation. This process ensures the ledger maintains immutability, meaning records cannot be changed once they are saved to the global network.  Created by former Google engineer Charlie Lee, the project is supported by the Litecoin Foundation, a non-profit organization dedicated to ecosystem adoption. Unlike many venture-backed projects, it is maintained by a decentralized community of independent developers and a global network of miners. The project has seen recent institutional adoption, with entities like Lite Strategy and Luxxfolio Holdings adding significant amounts of LTC to their corporate treasuries as of late 2025.

Litecoin

Litecoin is trending as investors debate its long-term potential as a reliable payment-focused digital asset versus its recent price underperformance compared to other crypto coins. The community is intensely focused on technical indicators, potential institutional interest, and the network's resilience as they watch for a breakout from current consolidation levels.

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending following positive Phase 3 results for its hereditary angioedema therapy, despite facing volatility from a recent equity offering. While some investors are concerned about dilution, community sentiment remains heavily focused on the stock's significant short interest, with many anticipating a potential squeeze driven by the company's long-term commercialization prospects.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is under intense market scrutiny following an FDA clinical hold placed on its RGX-111 and RGX-121 gene therapy programs due to a tumor found in a trial participant. The community is actively debating the implications for the February 8 PDUFA date for RGX-121, with many fearing a delay or rejection despite the company's efforts to advance its broader pipeline.

ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. Its product includes Epinephrine Nasal Spray. The company was founded by Richard Lowenthal, Robert Bell, and Sarina Tanimoto on August 5, 2015 and is headquartered in San Diego, CA.

ARS Pharmaceuticals Inc

SPRY is trending as investors digest news that the FDA has identified deficiencies in a competitors new drug application, effectively clearing a near-term runway for its needle-free epinephrine product. The community is actively discussing the potential for a major short squeeze, as the stock remains heavily shorted with a constrained float and growing global commercial momentum.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft.The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX's highly anticipated IPO has captured immense investor interest, driving its valuation to over $2 trillion and fueling widespread debate over whether its expansive AI infrastructure and orbital data center ambitions justify the premium pricing. While the community is sharply divided between those viewing the stock as a revolutionary long-term wealth creator and skeptics warning of a bubble driven by hype and unsustainable fundamentals, high trading volumes suggest strong institutional demand and significant retail participation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Durect (DRRX) Reports Q2 Loss, Tops Revenue Estimates

Durect (DRRX) delivered earnings and revenue surprises of +46.15% and +39.69%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Bausch Health Stock Falls on Q2 Earnings Miss, Revenues Beat

BHC stock falls 6.3% as Q2 earnings miss estimates despite stronger sales and growth in key segments like Salix and Solta Medical.

Catalyst Pharmaceutical (CPRX) Q1 Earnings and Revenues Top Estimates

DURECT Corp. focuses on advancing novel and potentially lifesaving investigational therapies derived from its Epigenetic Regulator Program. Its pipeline is called DUR-928, an endogenous sulfated oxysterol and an epigenetic regulator. The company was founded by James E. Brown and Felix Theeuwes on February 6, 1998 and is headquartered in Cupertino, CA.

DRRXDurect Corp

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest DRRX News